Huntington National Bank cut its holdings in Shire PLC (NASDAQ:SHPG) by 18.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,337 shares of the biopharmaceutical company’s stock after selling 1,405 shares during the quarter. Huntington National Bank’s holdings in Shire PLC were worth $971,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently modified their holdings of SHPG. Hartford Financial Management Inc. grew its position in Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 32 shares during the period. YorkBridge Wealth Partners LLC grew its position in shares of Shire PLC by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the period. Pacer Advisors Inc. bought a new stake in shares of Shire PLC during the 2nd quarter valued at $171,000. Iberiabank Corp bought a new stake in shares of Shire PLC during the 2nd quarter valued at $203,000. Finally, Stephens Inc. AR boosted its holdings in Shire PLC by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 228 shares during the period. Institutional investors and hedge funds own 18.27% of the company’s stock.
Shire PLC (SHPG) traded down $2.04 during trading on Tuesday, hitting $138.32. 632,800 shares of the stock were exchanged, compared to its average volume of 1,135,001. The stock has a market cap of $42,167.93, a P/E ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same quarter last year, the firm posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. equities research analysts forecast that Shire PLC will post 15 earnings per share for the current year.
Several brokerages have commented on SHPG. Liberum Capital upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Tuesday. Barclays PLC downgraded shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 price target (down from $216.00) on shares of Shire PLC in a report on Wednesday, August 9th. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 target price on shares of Shire PLC in a research note on Monday, October 2nd. Finally, BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $211.00.
COPYRIGHT VIOLATION WARNING: “Huntington National Bank Has $971,000 Holdings in Shire PLC (SHPG)” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://weekherald.com/2017/11/14/shire-plc-shpg-stake-lowered-by-huntington-national-bank.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.